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Introduction: Successful treatment of lung cancer patients with crizo-
tinib depends on the accurate diagnosis of anaplastic lymphoma receptor 
tyrosine kinase (ALK) gene rearrangements. The approved fluorescence 
in-situ hybridization test is complex and difficult to use in daily diagnos-
tic practice. Immunohistochemical assays—rapid and perfectly adapted 
for routine pathology practice—have been proposed as alternatives. We 
evaluated the novel high affinity ALK 1A4 antibody for routine diagnos-
tics in formalin fixed, paraffin-embedded tumor specimens.
Methods: Detection of ALK protein expression was investigated by 
comparing the new 1A4 antibody and the established D5F3 antibody/
Ventana system in 218 lung cancer specimens with known ALK status 
preanalyzed by quantitative reverse transcription-polymerase chain 
reaction and fluorescence in-situ hybridization (20 ALK-positive 
cases, 198 ALK-negative cases).
Results: The accuracy of both immunohistochemical assays for the 
detection of ALK rearrangements was high. Using a conventional stain-
ing procedure without signal enhancement, the 1A4 antibody assay 
identified all 20 ALK-rearranged tumors (100% sensitivity) and cor-
rectly characterized 196 of 198 negative cases (99.1% specificity). The 
D5F3/Ventana assay detected 19 ALK-rearranged tumors and typed 
217 of 218 tumors correctly (95% sensitivity, 99.5 % specificity).
Conclusions: The novel 1A4 antibody represents a promising candi-
date for screening lung tumors for the presence of ALK rearrangements.
Key Words: Lung adenocarcinoma, ALK, Immunohistochemistry, 
Antibody 1A4, Routine diagnostics.
(J Thorac Oncol. 2015;10: 713–716)
The identification of aberrantly activated tyrosine kinases in subsets of non–small-cell lung cancer (NSCLC) together 
with the development of specific kinase inhibitors has provided 
a major breakthrough in lung cancer therapy. Genomic rear-
rangements of the anaplastic lymphoma receptor tyrosine kinase 
(ALK) gene result in the formation of fusion proteins contain-
ing the ALK kinase domain.1,2 As a consequence, downstream 
signaling pathways implicated in cell growth and proliferation 
are constitutively activated. In lung adenocarcinoma, signaling 
of the activated tyrosine kinase can effectively be inhibited by 
the ALK inhibitor crizotinib.3,4 Patients with ALK-rearranged 
tumors who benefit from treatment, however, merely represent 
3%–6 % of adenocarcinoma patients,5 and reliable preselection 
by clinical or histopathological criteria hitherto is not possible. 
Given the high incidence of lung carcinoma, rapid screening for 
the identification of those few NSCLC patients with ALK rear-
rangements is desirable. Thus, the development of robust and 
reliable but also rapid and cost–effective laboratory tests is of 
importance. Currently, fluorescence in-situ hybridization (FISH) 
is the only approved diagnostic test to detect ALK rearrange-
ment which, however, requires specialized technical equipment, 
expertise and is a low-throughput approach. Quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) analysis 
reliably identifies ALK rearrangements by detecting unbalanced 
ALK transcript expression,6 but is not readily available as a rou-
tine method. Immunohistochemistry (IHC) is relatively inexpen-
sive, rapid, and perfectly adapted for routine pathology practice, 
therefore representing a promising candidate for a screening test. 
However, reliable detection of the low ALK protein expression in 
ALK-rearranged NSCLC turned out to be difficult. Depending on 
the affinity of the antibody, the sensitivity of the detection system, 
the scoring system, and the experience of the scorer ALK immu-
nostaining yields variable results. Substantial improvement was 
achieved by employing high affinity antibodies such as D5F3 and 
5A4 in combination with sensitive detection methods.7–9
The aim of this study was to evaluate the use of the novel 
ALK 1A4 antibody for routine diagnostics. The antibody 
was stained in a large cohort of adenocarcinoma specimens 
enriched for ALK-rearranged cases to determine the reliability 
of the assay to detect ALK rearrangements in comparison with 
the D5F3/Ventana system, qRT-PCR, and FISH.
MATERIALS AND METHODS
Specimen Collection
Two-hundred and eighteen lung adenocarcinoma spec-
imens with known ALK status (20 ALK-positive, 198 ALK-
negative) determined by qRT-PCR as described earlier6 were 
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studied. Break-apart FISH confirmed the result in all 20 ALK-
positive and 55 ALK-negative cases. Triplicate 0.6 mm cores 
from formalin-fixed paraffin-embedded tumor samples had 
been inserted into tissue microarrays (TMA). TMAs were used 
for all IHC analyses, and cases with ambiguous results were 
restained using full tissue sections. The study was approved 
by the ethics committee of the Eberhard-Karls-University 
Tübingen (Germany).
Immunohistochemistry
IHC was accomplished on 3-μm TMA or formalin-fixed 
paraffin-embedded tissue sections applying the monoclonal 
anti-ALK antibodies 1A4 (Origene, Rockville, MD) and D5F3 
(Ventana Medical Systems, Tucson, AZ). The D5F3 assay was 
performed using the Ventana Benchmark XT System, predi-
luted D5F3, the Optiview DAB detection kit and the Optiview 
Amplification kit according to the manufacturer’s instruc-
tions. The 1A4 assay was performed using the Leica BOND 
MAX System (Menarini Diagnostics, Berlin, Germany) with 
conventional DAB staining (no amplification). After heat-
induced epitope retrieval at pH 6.0, 1A4 (1:50) was incubated 
for 30 minutes, followed by washing and detection according 
to the manufacturer’s protocol. IHC was evaluated in a blinded 
fashion. For 1A4, ALK expression was assessed by estimat-
ing the intensity of cytoplasmic staining: 0/negative, no stain-
ing; 1+, faint; 2+, moderate; 3+, strong staining intensity in at 
least 10% tumor cells. D5F3/Ventana staining was classified 
as ALK-positive if there was any strong, granular, cytoplasmic 
staining; faint cytoplasmatic staining was regarded as negative 
according to the manufacturer’s instructions.
Quantitative Reverse Transcription-
Polymerase Chain Reaction
Unbalanced ALK transcript expression indicative of ALK 
gene rearrangement was measured by qRT-PCR amplification of 
the ALK 5′ and 3′ portions as previously described.6 Expression 
values were normalized to PGK1 and calculated relative to the 
average value in cell line RH30, which was arbitrarily defined 
as 1. The cut-off value for relevant expression was 0.3.
Fluorescence In-Situ Hybridization
FISH was performed as described applying a break-
apart probe specific for the ALK locus (ZytoLight SPEC 
ALK/EML4 TriCheck Probe; Zytomed Systems, Berlin, 
Germany).6
RESULTS
Two-hundred and eighteen NSCLC specimens with 
known ALK status as determined by qRT-PCR and FISH 
(20 ALK-positive, 198 ALK-negative cases) were analyzed 
for ALK protein expression using two different immunohis-
tochemical assays. The D5F3/Ventana assay produced more 
intense cytoplasmic signals, but higher background staining; 
the 1A4 antibody assay gave weaker cytoplasmic staining but 
less background. Concordance between IHC and qRT-PCR/
FISH data and representative immunohistochemical stainings 
are shown in Tables 1, 2, and Figure 1.
The 1A4 antibody assay identified all 20 ALK-
rearranged tumors (100% sensitivity) and predicted 196 of 
198 negative cases correctly (99.1% specificity; Table 1). In 
detail, 1A4 stained 17 cases with moderate to strong and five 
tumors with weak intensity (Table 2, Fig. 1). ALK rearrange-
ment was confirmed by both qRT-PCR and FISH in all tumors 
with moderate to strong protein expression and three of five 
cases revealing weak staining intensity. Although weak stain-
ing was only observed in ALK-positive cases with low to mod-
erate transcript expression (#21: 0.15, #16: 0.62; #11: 0.95), 
the staining intensity did not exactly correlate with transcript 
expression. Two cases (#118, #119) judged as 1+ were nega-
tive by FISH and failed to show unbalanced ALK transcript 
expression; they were therefore considered to be false-positive 
by IHC. No staining signal was observed in the remainder of 
196 cases without ALK rearrangement.
The D5F3/Ventana assay identified 19/20 ALK-
rearranged tumors and typed 217 of 218 tumors correctly 
(95% sensitivity, 99.5 % specificity; Table 1). All 19 ALK 
positive and ALK-rearranged cases showed a strong, granular 
cytoplasmic reactivity that did not correlate with the amount 
of ALK fusion transcripts (Table 2, Fig. 1). In three tumors, 
a weaker immunoreactivity with atypical or focal staining 
of small cytoplasmic spots (#21, #366) or membranous and 
cytoplasmic staining (#330) was seen (Fig. 1B). According 
to the manufacturer’s interpretation guidelines, these three 
cases were classified as negative. Although #330 and #366 
were confirmed as ALK-negative, #21 had an ALK transloca-
tion detected by FISH, resulting in a weak fusion transcript 
TABLE 1.  Summary of Immunohistochemical Staining Results for 218 Adenocarcinoma Cases
ALK Status
qRT-PCR/FISH n
IHC Using ALK Antibody 1A4 IHC Using ALK Antibody D5F3
Positiveb Criticalc Negative Positiveb Criticald Negative
Positivea 20 17 3 0 19 1 0
Negative 198 0 2 196 0 2 196
Total 218 17 5 196 19 3 196
aPositive refers to ALK rearrangement indicated by unbalanced ALK transcript expression and separated green and orange signals or single orange signals upon FISH.
bPositive refers to moderate or strong IHC staining in at least 10% tumor cells.
cFaint IHC staining scored as 1+.
dFocal IHC staining (judged as negative according to the manufacturer’s guidelines).
ALK, anaplastic large-cell lymphoma kinase; FISH, fluorescence in-situ hybridization; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; IHC, 
immunohistochemistry
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(expression level 0.15) and protein expression (scored as 1+ 
using 1A4). Of 198 ALK-negative cases, 196 were undoubt-
edly scored as negative. Ten cases showed background staining 
of tumor cells and macrophages and were judged as negative 
according to the manufacturer’s guidelines.
DISCUSSION
Immunohistochemical stainings of a panel of lung adeno-
carcinoma specimens using the novel ALK antibody 1A4 and 
the D5F3/Ventana system yielded highly concordant results. 
Both systems typed more than 99% tumor specimens correctly. 
Notably, the 1A4 assay detected all (100% sensitivity), and the 
D5F3/Ventana system all but one of the ALK-rearranged cases 
(95% sensitivity). Other studies report on a sensitivity of 83%–
100% with D5F3/Ventana9–11 and 95% with 5A4/Ventana12 
(both with signal amplification), and 100% with D5F38,7 and 
83%–100% with 5A48,9,10,11,13 using signal enhancement. In most 
studies, a high correlation in predicting ALK rearrangements 
was reached using D5F3 or 5A4 in combination with highly 
sensitive detection methods. In contrast, 1A4 IHC was per-
formed using a conventional staining procedure, without signal 
enhancement. The D5F3/Ventana assay produced more intense 
cytoplasmic signals than 1A4 but with higher background and 
focal staining. Likely, this is the consequence of a tyramide sig-
nal amplification step incorporated into the Ventana assay; it 
demands experienced and trained evaluation.
IHC detects ALK rearrangements independent of the 
fusion partner and represents a suitable screening approach. If 
applied in routine diagnostics of NSCLC, it is expected to drasti-
cally reduce molecular pathological efforts. In our study, discor-
dant IHC results in comparison with qRT-PCR/FISH were rare 
(1A4: two cases; D5F3: three cases) and restricted to cases with 
faint or focal immunostaining. Therefore, only tumors with weak 
1A4 staining (2.3% in our series) or focal D5F3 staining (1.4% 
in our series) needed to be reanalyzed using alternative assays as 
qRT-PCR or FISH. In other words, 98% NSCLC were reliably 
predicted in a fast and cost–effective manner using IHC alone.
Not to overlook “druggable” tumors is the critical issue 
in ALK diagnostics. Therefore, up-regulated expression of 
nonrearranged ALK transcripts associated with detectable 
amounts of ALK protein is a critical finding that was observed 
in 1.1% of 523 NSCLC specimens.6 Reinvestigation of those 
cases in this study was not possible due to exhaustion of tumor 
material. Expression of nonrearranged ALK transcripts may 
be relevant for ALK inhibitor therapy in NSCLC, because 
(1) ALK-inhibitor treatment of NSCLC cells and xenograft 
TABLE 2.  Molecular Data of Adenocarcinoma Cases Positive for ALK Immunostaining
Case No.
qRT-PCRa FISHb Immunohistochemistry
ALK 3′ Portion ALK 5′ Portion ALK Break-Apart Probe ALK Antibody 1A4 ALK Antibody D5F3
62 3.84 0.01 Translocation with deletion 3+ Positive
14 0.72 0.02 Translocation with deletion 3+ Positive
9 1.03 0.00 Translocation 3+ Positive
3 5.94 0.02 Translocation 2+ Positive
2 6.23 0.03 Translocation 2+ Positive
10 1.01 0.16 Translocation 2+ Positive
8 1.30 0.01 Translocation 2+ Positive
17 0.55 0.00 Translocation with deletion 2+ Positive
7 1.58 0.01 Translocation with deletion 2+ Positive
19 0.41 0.01 Translocation 2+ Positive
6 1.84 0.00 Translocation with deletion 2+ Positive
133 1.96 0.00 Translocation 2+ Positive
137 0.79 0.02 Translocation 2+ Positive
964 0.93 0.00 Translocation 2+ Positive
967 1.61 0.02 Translocation 2+ Positive
965 0.57 0.01 Translocation 2+ Positive
11 0.95 0.19 Translocation with deletion 1+ Positive
16 0.62 0.11 Translocation 1+ Positive
140 0.25 0.00 Translocation 2+ Positive
21 0.15 0.01 Translocation 1+ Focal staining
118 0.04 0.01 Wild type 1+ Negative
119 0.01 0.02 Wild type 1+ Negative
330 0.03 0.04 Wild type Negative Focal staining
366 0.01 0.00 Wild type Negative Focal staining
aALK transcript expression was measured by qRT-PCR amplification of the ALK 5′ and 3′ portion normalized to PGK1 and calculated relative to the average value in cell line RH30, 
which was arbitrarily defined as 1. Cases #140 and #21 had a low, yet unbalanced expression.
bTranslocation refers to ALK rearrangement indicated by separated green and orange signals upon FISH. Translocation with deletion refers to ALK translocation with deletion of 
the ALK 5′ portion indicated by single orange signals.
ALK, anaplastic large-cell lymphoma kinase; FISH, fluorescence in-situ hybridization; qRT-PCR, quantitative reverse transcription-polymerase chain reaction
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tumors expressing wild-type ALK transcripts resulted in 
tumor regression and suppression of metastasis;14 and (2) a 
reported IHC-positive, but FISH-negative patient was treated 
with crizotinib and showed a dramatic therapy response.15 It 
should be mentioned, however, that a rare false-negative FISH 
result cannot reliably be excluded for this case, because the 
lack of rearrangement was not confirmed by other methods. 
IHC detects ALK protein overexpression in tumors with 
gene fusions and transcriptional up-regulation, but does not 
distinguish between the two. Therefore, until the question of 
whether tumors expressing nonrearranged ALK can be treated 
with crizotinib is answered, we propose a diagnostic screen-
ing algorithm using a sensitive IHC assay as a screening test, 
followed by further investigation of IHC-positive and ques-
tionable cases only. In more specific terms, this means that 
cases showing any ALK expression by IHC would be tested by 
qRT-PCR or FISH for confirmation of ALK positivity; cases 
with no ALK expression by IHC would be considered ALK-
negative, and would not have to be tested further. Even if this 
algorithm is applied, routine diagnostic efforts are expected to 
be significantly reduced by prescreening of tumors with IHC.
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FIgURE 1.  Examples of ALK staining 
in adenocarcinoma specimens using 
antibodies 1A4 and D5F3. A, concor-
dant, B discordant results. A, Distinct 
cytoplasmic staining with differing 
intensity in three specimens with 
ALK translocations (#14, #7, #11). 
An ALK-negative case #42 is nega-
tive with both immunohistochemical 
assays. B, Case #21 with ALK trans-
location and weak fusion transcript 
expression shows weak cytoplasmic 
staining with 1A4 (1+) and focal 
cytoplasmic staining of small spots 
with D5F3 (negative according to 
the manufacturer’s guidelines). Focal 
staining with D5F3 is also seen in two 
ALK-negative tumors (#366, #330), 
both negative with 1A4. Case #119 
(ALK-negative according to qRT-PCR) 
is clearly negative with D5F3 but 
weakly positive with 1A4 (1+). Scale 
bar 50 μm.
